Cell Therapy Developer Artiva Refiles for a $100M IPO

Seeking AlphaJun 29 10:07 ET

Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25

Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 0.0% and

moomoo NewsJun 17 22:33 ET · Ratings

Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.

Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.

Dow JonesJun 13 10:34 ET

Affimed Is Maintained at Buy by Laidlaw & Co.

Affimed Is Maintained at Buy by Laidlaw & Co.

Dow JonesJun 13 10:34 ET

Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating

Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5% o

moomoo NewsJun 13 07:32 ET · Ratings

Laidlaw Initiates Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25

Laidlaw analyst Yale Jen initiates coverage on $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 29.7% and a total

moomoo NewsJun 13 06:31 ET · Ratings